PMID- 34171173
OWN - NLM
STAT- MEDLINE
DCOM- 20220415
LR  - 20220731
IS  - 1464-410X (Electronic)
IS  - 1464-4096 (Print)
IS  - 1464-4096 (Linking)
VI  - 129
IP  - 4
DP  - 2022 Apr
TI  - Systemic therapies for metastatic hormone-sensitive prostate cancer: network 
      meta-analysis.
PG  - 423-433
LID - 10.1111/bju.15507 [doi]
AB  - OBJECTIVES: To perform a systematic review and network meta-analysis to compare 
      the efficacy and safety of currently available treatments for the management of 
      metastatic hormone-sensitive prostate cancer (mHSPC), as there has been a 
      paradigm shift with the use of next-generation androgen receptor inhibitors 
      (ARIs) and docetaxel. METHODS: Multiple databases were searched for articles 
      published before May 2020 according to the Preferred Reporting Items for 
      Systematic Review and Meta-analysis extension statement for network 
      meta-analysis. Studies comparing overall/progression-free survival (OS/PFS) 
      and/or adverse events (AEs) in patients with mHSPC were eligible. RESULTS: Nine 
      studies (N = 9960) were selected, and formal network meta-analyses were 
      conducted. Abiraterone (hazard ratio [HR] 0.83, 95% credible interval [CrI] 
      0.76-0.90), docetaxel (HR 0.90, 95% CrI 0.82-0.98), and enzalutamide (HR 0.85, 
      95% CrI 0.73-0.99) were associated with significantly better OS than 
      androgen-deprivation therapy (ADT), and abiraterone emerged as the best option. 
      Abiraterone (HR 0.71, 95% CrI 0.67-0.76), apalutamide (HR 0.73, 95% CrI 
      0.65-0.81), docetaxel (HR 0.84, 95% CrI 0.78-0.90), and enzalutamide (HR 0.67, 
      95% CrI 0.63-0.71) were associated with significantly better PFS than ADT, and 
      enzalutamide emerged as the best option. Abiraterone (HR 0.85, 95% CrI 
      0.78-0.93), apalutamide (HR 0.87, 95% CrI 0.77-0.98), and enzalutamide (HR 0.80, 
      95% CrI 0.73-0.88) were significantly more effective than docetaxel. Regarding 
      AEs, apalutamide was the likely best option among the three ARIs. In patients 
      with low-volume mHSPC, enzalutamide was the best option in terms of OS and PFS. 
      CONCLUSIONS: All three ARIs are effective therapies for mHSPC; apalutamide was 
      the best tolerated. All three seemed more effective than docetaxel. These 
      findings may facilitate individualised treatment strategies and inform future 
      comparative trials.
CI  - (c) 2021 The Authors. BJU International published by John Wiley & Sons Ltd on 
      behalf of BJU International.
FAU - Mori, Keiichiro
AU  - Mori K
AUID- ORCID: 0000-0002-6147-6569
AD  - Department of Urology, Medical University of Vienna, Vienna, Austria.
AD  - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
FAU - Mostafaei, Hadi
AU  - Mostafaei H
AUID- ORCID: 0000-0001-5596-1771
AD  - Department of Urology, Medical University of Vienna, Vienna, Austria.
AD  - Research Center for Evidence Based Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Sari Motlagh, Reza
AU  - Sari Motlagh R
AUID- ORCID: 0000-0002-3819-9911
AD  - Department of Urology, Medical University of Vienna, Vienna, Austria.
FAU - Pradere, Benjamin
AU  - Pradere B
AD  - Department of Urology, Medical University of Vienna, Vienna, Austria.
FAU - Quhal, Fahad
AU  - Quhal F
AD  - Department of Urology, Medical University of Vienna, Vienna, Austria.
AD  - Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
FAU - Laukhtina, Ekaterina
AU  - Laukhtina E
AUID- ORCID: 0000-0002-8953-0272
AD  - Department of Urology, Medical University of Vienna, Vienna, Austria.
AD  - Institute for Urology and Reproductive Health, Sechenov University, Moscow, 
      Russia.
FAU - Schuettfort, Victor M
AU  - Schuettfort VM
AD  - Department of Urology, Medical University of Vienna, Vienna, Austria.
AD  - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany.
FAU - Kramer, Gero
AU  - Kramer G
AD  - Department of Urology, Medical University of Vienna, Vienna, Austria.
FAU - Abufaraj, Mohammad
AU  - Abufaraj M
AUID- ORCID: 0000-0002-6603-6319
AD  - Department of Urology, Medical University of Vienna, Vienna, Austria.
AD  - Division of Urology, Department of Special Surgery, The University of Jordan, 
      Amman, Jordan.
FAU - Karakiewicz, Pierre I
AU  - Karakiewicz PI
AD  - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health 
      Centre, Montreal, Canada.
FAU - Kimura, Takahiro
AU  - Kimura T
AD  - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
FAU - Egawa, Shin
AU  - Egawa S
AD  - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
FAU - Shariat, Shahrokh F
AU  - Shariat SF
AD  - Department of Urology, Medical University of Vienna, Vienna, Austria.
AD  - Institute for Urology and Reproductive Health, Sechenov University, Moscow, 
      Russia.
AD  - Division of Urology, Department of Special Surgery, The University of Jordan, 
      Amman, Jordan.
AD  - Department of Urology, Weill Cornell Medical College, New York, NY, USA.
AD  - Department of Urology, University of Texas Southwestern, Dallas, TX, USA.
AD  - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.
AD  - Department of Urology, Second Faculty of Medicine, Charles University, Prague, 
      Czech Republic.
AD  - European Association of Urology Research Foundation, Arnhem, Netherlands.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20210721
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
RN  - 0 (Androgen Antagonists)
RN  - 0 (Androgen Receptor Antagonists)
RN  - 0 (Hormones)
RN  - 15H5577CQD (Docetaxel)
SB  - IM
MH  - *Androgen Antagonists/adverse effects
MH  - Androgen Receptor Antagonists
MH  - Docetaxel/therapeutic use
MH  - Hormones
MH  - Humans
MH  - Male
MH  - Network Meta-Analysis
MH  - *Prostatic Neoplasms/pathology
PMC - PMC9291853
OTO - NOTNLM
OT  - #PCSM
OT  - #ProstateCancer
OT  - androgen receptor inhibitors
OT  - docetaxel
OT  - metastatic hormone-sensitive prostate cancer
OT  - network meta-analysis
COIS- We certify that all conflicts of interest, including specific financial interests 
      and relationships and affiliations relevant to the subject matter or materials 
      discussed in the manuscript are the following: Shahrokh Shariat owns or co-owns 
      the following patents: Methods to determine prognosis after therapy for prostate 
      cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for 
      bladder cancer. Granted 2003-06-19. Prognostic methods for patients with 
      prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the 
      detection of bladder transitional cell carcinoma. Granted 2010-07-20. He has a 
      consulting or advisory role for the following: Astellas, Astra Zeneca, Bayer, 
      BMS, Cepheid, Ferring, Ipsen, Jansen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, 
      Roche, Sanochemia, Sanofi, Takeda, Urogen, Wolff. The other authors made no 
      disclosures.
EDAT- 2021/06/26 06:00
MHDA- 2022/04/16 06:00
PMCR- 2022/07/18
CRDT- 2021/06/25 17:27
PHST- 2021/06/26 06:00 [pubmed]
PHST- 2022/04/16 06:00 [medline]
PHST- 2021/06/25 17:27 [entrez]
PHST- 2022/07/18 00:00 [pmc-release]
AID - BJU15507 [pii]
AID - 10.1111/bju.15507 [doi]
PST - ppublish
SO  - BJU Int. 2022 Apr;129(4):423-433. doi: 10.1111/bju.15507. Epub 2021 Jul 21.